Physician profile
Corin Agoris
NPI 1801389226
$5,346.19
in general payments reported to CMS, 2019-2025
27 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.82 · 2020: $31.62 · 2021: $100 · 2022: $690 · 2023: $707 · 2024: $1,628 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,456 · Education: $25.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.40 |
| Education | $25.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,107.26 | 2021-2025 | Evenity, Prolia, Enbrel |
| Ucb, INC. | $695.00 | 2022-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $572.95 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $458.85 | 2021-2025 | Taltz |
| Janssen Biotech, INC. | $449.28 | 2022-2025 | Tremfya, Simponi Aria |
| Genzyme Corporation | $326.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $213.46 | 2022-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $191.44 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $179.30 | 2023-2025 | Strensiq |
| Pfizer INC. | $154.17 | 2024-2025 | |
| Radius Health, INC. | $153.98 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $124.25 | 2021-2024 | Saphnelo |
| Scilex Pharmaceuticals INC. | $117.01 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $100.34 | 2021-2023 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $74.28 | 2024-2025 | Jubbonti, Hyrimoz |
| Sobi, INC | $71.66 | 2022-2024 | |
| Genentech USA, INC. | $51.11 | 2024-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $45.02 | 2023-2025 | |
| Organon LLC | $32.92 | 2022-2024 | |
| Abiomed | $31.62 | 2020 | |
| Fidia Pharma USA INC. | $29.11 | 2024-2025 | Hymovis, Triluron, Hyalgan |
| Mallinckrodt Hospital Products INC. | $24.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.51 | 2023 | Truxima |
| Kiniksa Pharmaceuticals International, Plc | $16.18 | 2024 | Arcalyst |
| Shionogi INC | $14.68 | 2019 | |
| Edwards Lifesciences Corporation | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corin Agoris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.